Literature DB >> 11451842

Prevention of nosocomial urinary tract infection in ICU patients: comparison of effectiveness of two urinary drainage systems.

M Leone1, F Garnier, M Dubuc, M C Bimar, C Martin.   

Abstract

STUDY
OBJECTIVES: To determine whether the rate of acquisition of bacteriuria differs between the use of a complex closed drainage system (CCDS) with a preattached catheter, antireflux valve, drip chamber, and povidone-iodine releasing cartridge, and a two-chamber open drainage system (TCOS) in ICU patients.
DESIGN: Prospective, nonrandomized, controlled trial.
SETTING: Medical/surgical/trauma ICU in a university hospital. PATIENTS: Two hundred twenty-four ICU patients requiring an indwelling urinary catheter. INTERVENTION: We compared the rate of acquisition of bacteriuria in two groups of consecutive patients (n = 113 and n = 111, respectively) who underwent bladder catheterization with a TCOS during the first 6 months and with a CCDS during the next 6 months. Urinary catheters were managed by a team of trained nurses following the same written protocol. No prophylactic antibiotics were administered, either during management of catheter placements or catheter withdrawal, but 75% of patients received one or more antimicrobial medications for treatment of infected sites other than the urinary tract. Urine samples were obtained weekly for the duration of catheterization and within 24 h after catheter removal, and each time symptoms of urinary infection were suspected. Only patients who required an indwelling catheter for > 48 h were evaluated. MEASUREMENTS AND
RESULTS: There was no statistical difference in the rate of bacteriuria between the two groups. Bacteriuria occurred in 11.5% and 13.5% of patients, and was diagnosed on day 14 +/- 8 and 13 +/- 9 of catheterization (mean +/- SD) for the TCOS and the CCDS, respectively. A CCDS cost $3 (US dollars) more than the TCOS.
CONCLUSIONS: To our knowledge, this is the first study to compare the effectiveness of a TCOS and a CCDS in ICU patients. No differences were noted between the two systems (alpha = 0.05). The higher cost of a CCDS is not justified for ICU patients.

Entities:  

Mesh:

Year:  2001        PMID: 11451842     DOI: 10.1378/chest.120.1.220

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Quality indicators for ICU: ISCCM guidelines for ICUs in India.

Authors:  B Ray; D P Samaddar; S K Todi; N Ramakrishnan; George John; Suresh Ramasubban
Journal:  Indian J Crit Care Med       Date:  2009-10

2.  Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit.

Authors:  Marc Leone; Jacques Albanèse; Franck Garnier; Christophe Sapin; Karine Barrau; Marie-Christine Bimar; Claude Martin
Journal:  Intensive Care Med       Date:  2003-04-09       Impact factor: 17.440

3.  A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients.

Authors:  Marc Leone; Anne-Sophie Perrin; Isabelle Granier; Pierre Visintini; Valery Blasco; François Antonini; Jacques Albanèse; Claude Martin
Journal:  Intensive Care Med       Date:  2007-02-09       Impact factor: 17.440

4.  Comparison of effectiveness of two urinary drainage systems in intensive care unit: a prospective, randomized clinical trial.

Authors:  Marc Leone; Franck Garnier; François Antonini; Marie-Christine Bimar; Jacques Albanèse; Claude Martin
Journal:  Intensive Care Med       Date:  2003-02-08       Impact factor: 17.440

5.  Complicated urinary tract infection in adults.

Authors:  L E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

6.  Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit.

Authors:  Marc Leone; Jacques Albanèse; Franck Garnier; Christophe Sapin; Karine Barrau; Marie-Christine Bimar; Claude Martin
Journal:  Intensive Care Med       Date:  2003-05-13       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.